Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, Augu...(or the acute treatment of central nervou...),Health

Date:7/27/2009

or the acute treatment of central nervous system conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

The Company has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and it has advanced AZ-104 (Staccato loxapine) into Phase 2b testing. Both product candidates are being developed for the acute treatment of migraine headache. AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subj
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. A Random Act of Kindness Changes a Familys Life Forever as Alexzander Prados Wish to Walk is Granted at Abilities Expo
2. Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
3. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
4. Alexzas Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference
5. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
6. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
7. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
8. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
9. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
10. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
11. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008